<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04497805</url>
  </required_header>
  <id_info>
    <org_study_id>ALLO-ASC-SHEET</org_study_id>
    <nct_id>NCT04497805</nct_id>
  </id_info>
  <brief_title>Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers</brief_title>
  <official_title>A Phase 2 Clinical Study to Evaluate The Efficacy and Safety of ALLO-ASC-SHEET in the Subjects With Diabetic Wagner Grade II Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anterogen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anterogen Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 double-blind clinical study to evaluate the efficacy and Safety of&#xD;
      ALLO-ASC-SHEET in subjects with Diabetic Wagner Grade II Foot Ulcers, compared to placebo&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportions of subjects who achieved complete wound closure.</measure>
    <time_frame>During 12 weeks</time_frame>
    <description>Proportions of subjects who achieved complete wound closure during the 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to initial complete wound closure between the 2 groups.</measure>
    <time_frame>During 12 weeks</time_frame>
    <description>Measure the time to initial complete wound closure between the 2 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in wound size compared to baseline between the 2 groups.</measure>
    <time_frame>During 12 weeks</time_frame>
    <description>Wound size is measured by using eKare 3D Wound Measurement system(Mobile Devices).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects who achieved complete wound closure between the 2 groups by the classification of wound size.</measure>
    <time_frame>During 12 weeks</time_frame>
    <description>Proportions of subjects who achieved complete wound closure by the classification of wound size, 1.5~7 cm2 and 7.1~15 cm2 between the 2 groups at every visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects who achieved complete wound closure between the 2 groups by the classification of location of diabetic foot ulcer.</measure>
    <time_frame>During 12 weeks</time_frame>
    <description>Proportions of subjects who achieved complete wound closure by the classification of location of diabetic foot ulcer, plantar and dorsal between the 2 groups at every visit by post-hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durability of complete wound closure for the additional 24 weeks.</measure>
    <time_frame>During 36 weeks</time_frame>
    <description>Durability of complete wound closure for the additional 24 weeks from the initial complete wound closure.&#xD;
Wound size is measured by using eKare 3D Wound Measurement system(Mobile Devices).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>ALLO-ASC-SHEET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALLO-ASC-SHEET Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrogel SHEET(Vehicle control)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Control Hydrogel sheet without allogenic adipose-derived mesenchymal stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALLO-ASC-SHEET</intervention_name>
    <description>Hydrogel sheet containing Allogenic Mesenchymal Stem Cells</description>
    <arm_group_label>ALLO-ASC-SHEET</arm_group_label>
    <arm_group_label>Hydrogel SHEET(Vehicle control)</arm_group_label>
    <other_name>Hydrogel sheet containing Allogenic Mesenchymal Stem Cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female between 18 and 80 years of age.&#xD;
&#xD;
          2. Diagnosed with Type I or Type II diabetes and has Wagner Grade II diabetic foot ulcers&#xD;
             for longer than 4 weeks at the time of screening.&#xD;
&#xD;
          3. Foot ulcer located in the plantar or dorsal, with ulcer size between1.5 cm2 and 15&#xD;
             cm2.&#xD;
&#xD;
          4. Ulcer, Graded II by Wagner grade, and extended to muscle periosteum, muscle, tendon,&#xD;
             or joint capsule, but not to bone.&#xD;
&#xD;
          5. Ulcer is free of necrotic debris,exhibits no signs of clinical infection.&#xD;
&#xD;
          6. Ulcer area blood circulation meets 1 of the following criteria:&#xD;
&#xD;
             A. Blood vessels around the ulcer detected by Doppler Test to have biphasic or&#xD;
             triphasic flow B. Range of Ankle Brachial Index(ABI) is&gt;0.7 to &lt;1.3 C. Transcutaneous&#xD;
             oxygen pressure (TcPO2) &gt;30 mmHg.&#xD;
&#xD;
          7. Is able to give written informed consent prior to study start and to comply with the&#xD;
             study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ulcer is of non-diabetic pathophysiology.&#xD;
&#xD;
          2. The ulcer has increased or decreased in size by ≥30% during 2 weeks screening period.&#xD;
&#xD;
          3. Patient is currently on higher dose antibiotic therapy as defined by increased dose or&#xD;
             change in therapy from the initial treatment regimen at screening to treat index wound&#xD;
             infection or patient is on suppressive antibiotic therapy for diabetic foot wound&#xD;
             infection.&#xD;
&#xD;
          4. The longest dimension of the index wound exceeds 15 cm at the baseline visit.&#xD;
&#xD;
          5. Patient with skin lesion confirmed by biopsy (when Investigator deems suspicious) and&#xD;
             then judged by Investigator to be an etiology other than diabetic foot ulcer&#xD;
             (i.e.,example skin cancer in situ, pyoderma).&#xD;
&#xD;
          6. Current evidence of active charcot, osteomyelitis, cellulitis, or evidence of other&#xD;
             infection including fever or purulentdrainage from wound site.&#xD;
&#xD;
          7. Is Human Immunodeficiency Virus (HIV) positive&#xD;
&#xD;
          8. Havesevere hepatic deficiencies.&#xD;
&#xD;
          9. Have a glycated hemoglobin A1c (HbA1c) level of &gt;10%.&#xD;
&#xD;
         10. Have an allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue.&#xD;
&#xD;
         11. Have severe renal function insufficiency documented with creatinine greater than 3.0&#xD;
             mg/dL.&#xD;
&#xD;
         12. Pregnant or breast-feeding.&#xD;
&#xD;
         13. Is unwilling to use an &quot;effective&quot; method of contraception during the study.&#xD;
&#xD;
         14. Have evidence of current infection including purulent drainage from the wound site.&#xD;
&#xD;
         15. Have a clinically relevant history of alcohol or drugs abuse.&#xD;
&#xD;
         16. Have postprandialblood sugar &gt;350 mg/dL at screening.&#xD;
&#xD;
         17. Is not able to comply with the study requirements.&#xD;
&#xD;
         18. Is considered by the Investigator to have a significant disease which might impact the&#xD;
             study.&#xD;
&#xD;
         19. Is considered not suitable for the study by Investigator.&#xD;
&#xD;
         20. Have a history of malignancy within the last 5 years (except basal cell carcinoma in&#xD;
             situ).&#xD;
&#xD;
         21. Is currently or were enrolled in another clinical study within 60 days of screening.&#xD;
&#xD;
         22. Have undergone wound treatments with growth factors, dermal substitutes, or other&#xD;
             biological therapies within the last 30 days.&#xD;
&#xD;
         23. Is receiving oral or parenteral corticosteroids (In doses greater than 10 mg per day),&#xD;
             any immunosuppressive, or cytotoxic agents with unstable dose prior to 4 weeks from&#xD;
             screening.&#xD;
&#xD;
         24. Cannot maintain off-loading process.&#xD;
&#xD;
         25. Panel reactive antibody (PRA) levels ≥ 20% at screening.&#xD;
&#xD;
         26. Venereal Disease Research Laboratory test (VDRL) or RPR positive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yun Jung Choi, PM</last_name>
    <role>Study Director</role>
    <affiliation>Anterogen Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yun Jung Choi, PM</last_name>
    <phone>82 10 9199 0164</phone>
    <email>yunjungchoi@anterogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessi Choi, PM</last_name>
    <phone>82 10 9199 0164</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Armstrong, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 15, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2020</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

